Published in BMC Cancer on April 30, 2014
Dietary Iodine Sufficiency and Moderate Insufficiency in the Lactating Mother and Nursing Infant: A Computational Perspective. PLoS One (2016) 1.40
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer. Biomed Res Int (2016) 0.85
Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand [(18)F]-tetrafluoroborate. EJNMMI Res (2015) 0.78
Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation. Sci Rep (2016) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Triple-negative breast cancer. N Engl J Med (2010) 11.39
A survey of telomerase activity in human cancer. Eur J Cancer (1997) 10.84
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Cloning and characterization of the thyroid iodide transporter. Nature (1996) 3.54
The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev (2003) 3.48
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med (2000) 3.01
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia (2001) 2.67
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab (2003) 1.73
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer (2006) 1.66
TRANSPORT OF IODIDE AND OTHER ANIONS IN THE THYROID GLAND. Physiol Rev (1964) 1.57
The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res (2004) 1.52
Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res (2000) 1.49
In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther (2001) 1.44
Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther (2010) 1.44
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem (2001) 1.40
Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology (1997) 1.32
N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model. J Biol Chem (1998) 1.28
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A (2000) 1.23
The Na+/I- symporter (NIS): mechanism and medical impact. Endocr Rev (2013) 1.21
Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther (2005) 1.19
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol (2008) 1.13
Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol (2009) 1.13
Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther (2007) 1.13
The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther (2012) 1.12
Expression of Na+/I- symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab (2000) 1.10
Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol (2001) 1.10
Characterization of the sequences of the human cytomegalovirus enhancer that mediate differential regulation by natural and synthetic retinoids. Mol Endocrinol (1996) 1.07
Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther (2006) 1.04
Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther (2000) 1.04
Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res (2009) 1.04
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 1.04
Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology (1997) 1.02
Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology (2005) 1.02
Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology (2005) 1.02
A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther (2005) 1.02
Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res (1983) 1.01
Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab (1999) 1.00
Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol (2011) 0.98
The Na+/I- symporter mediates active iodide uptake in the intestine. Am J Physiol Cell Physiol (2008) 0.98
Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest (2004) 0.98
Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand (2002) 0.97
Iodine in human milk: perspectives for infant health. Nutr Rev (2001) 0.97
Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. Mol Endocrinol (2006) 0.97
PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer (2007) 0.96
Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models. Cancer Res (2004) 0.96
Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid (2013) 0.96
Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J Clin Endocrinol Metab (2005) 0.95
Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat (2003) 0.95
The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One (2011) 0.94
Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin Cancer Res (2009) 0.94
Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res Treat (2007) 0.93
Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther (2011) 0.93
Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens. Cancer Epidemiol Biomarkers Prev (2007) 0.93
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res (2009) 0.93
Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol (2009) 0.92
Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab (2000) 0.92
Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol (1999) 0.91
Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med (2013) 0.90
Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. Eur J Endocrinol (2008) 0.89
Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. Thyroid (2007) 0.88
The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue. Cancer Res Treat (2005) 0.88
Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Hum Gene Ther (2011) 0.88
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS). Breast Cancer Res Treat (2010) 0.88
Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer (2007) 0.88
Breast cancer brain metastases express the sodium iodide symporter. J Neurooncol (2009) 0.87
Targeting of tumor radioiodine therapy by expression of the sodium iodide symporter under control of the survivin promoter. Cancer Gene Ther (2010) 0.87
In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther (2007) 0.87
Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther (2004) 0.87
Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab (2013) 0.87
Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line. J Clin Endocrinol Metab (2004) 0.87
Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther (2008) 0.87
Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer (2007) 0.86
Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells. PLoS One (2012) 0.86
Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res (2009) 0.86
Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol (2004) 0.86
Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol (2000) 0.85
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. Gastroenterology (2007) 0.85
Active transport of iodide and other anions across the choroid plexus. J Physiol (1974) 0.85
Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther (2010) 0.85
Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab (2007) 0.84
Enhanced anti-tumor effects of combined MDR1 RNA interference and human sodium/iodide symporter (NIS) radioiodine gene therapy using an adenoviral system in a colon cancer model. Cancer Gene Ther (2010) 0.83
Expression of the Na(+)/I(-) symporter in invasive ductal breast cancer. Folia Histochem Cytobiol (2003) 0.83
The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells. Cell Death Dis (2013) 0.83
Targeting histone deacetylase in thyroid cancer. Expert Opin Ther Targets (2012) 0.83
Radioiodine treatment of well-differentiated thyroid cancer. Endocrine (2012) 0.83
Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res (2012) 0.83
Regulation of sodium iodide symporter gene expression by Rac1/p38β mitogen-activated protein kinase signaling pathway in MCF-7 breast cancer cells. J Biol Chem (2011) 0.82
Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining. J Clin Endocrinol Metab (2008) 0.82
Intronic elements in the Na+/I- symporter gene (NIS) interact with retinoic acid receptors and mediate initiation of transcription. Nucleic Acids Res (2010) 0.82
Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of ¹³¹I by carbamazepine in breast cancer cells. Breast Cancer Res Treat (2010) 0.82
Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer. BMC Res Notes (2011) 0.82
Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer (2012) 0.82
Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. Endocrine (2011) 0.81
Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab (2006) 2.81
The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal (2005) 2.75
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol (2003) 2.69
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology (2003) 2.31
Laparoendoscopic single-site upper urinary tract surgery: assessment of postoperative complications and analysis of risk factors. Eur Urol (2011) 2.30
Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost (2008) 1.69
Muscle- and nerve-sparing bulbar urethroplasty: a new technique. Eur Urol (2008) 1.63
Subfunctionalization of duplicated zebrafish pax6 genes by cis-regulatory divergence. PLoS Genet (2008) 1.59
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: nephrolithotomy in 189 patients with solitary kidneys. J Endourol (2011) 1.55
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Dornier Lithotripter S 220 F EMSE: the first report of over 1000 treatments. Urology (2009) 1.48
A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J Neuroinflammation (2013) 1.34
Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res (2005) 1.33
Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab (2005) 1.30
Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer (2002) 1.28
Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. Thyroid (2014) 1.25
Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells. Proteomics (2009) 1.23
Case-control study of toenail cadmium and prostate cancer risk in Italy. Sci Total Environ (2006) 1.21
Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. J Clin Endocrinol Metab (2010) 1.16
Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab (2013) 1.16
HABP2 Mutation and Nonmedullary Thyroid Cancer. N Engl J Med (2015) 1.15
Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab (2008) 1.14
APE1/Ref-1 regulates PTEN expression mediated by Egr-1. Free Radic Res (2008) 1.13
Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab (2004) 1.12
Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care (2007) 1.09
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol Rep (2001) 1.08
Is telesurgery a new reality? Our experience with laparoscopic and percutaneous procedures. J Endourol (2003) 1.08
Selective activation of the transcription factor ATF6 mediates endoplasmic reticulum proliferation triggered by a membrane protein. Proc Natl Acad Sci U S A (2011) 1.07
Benign intratesticular schwannoma: a rare finding. Asian J Androl (2006) 1.06
Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab (2015) 1.04
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care (2012) 1.04
Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors. J Clin Endocrinol Metab (2002) 1.04
A proteomic approach to identify early molecular targets of oxidative stress in human epithelial lens cells. Biochem J (2004) 1.03
A de novo nonsense mutation of PAX6 gene in a patient with aniridia, ataxia, and mental retardation. Am J Med Genet A (2007) 1.03
Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab (2009) 1.03
Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology (2005) 1.02
Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T: preliminary results. J Comput Assist Tomogr (2006) 1.02
A deletion 3' to the PAX6 gene in familial aniridia cases. Mol Vis (2007) 1.01
Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol (2003) 1.01
Expression of Dicer and Drosha in triple-negative breast cancer. J Clin Pathol (2012) 1.00
Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol (2005) 0.99
Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol (2011) 0.98
HEX expression and localization in normal mammary gland and breast carcinoma. BMC Cancer (2006) 0.98
Cross-regulation between Egr-1 and APE/Ref-1 during early response to oxidative stress in the human osteoblastic HOBIT cell line: evidence for an autoregulatory loop. Free Radic Res (2005) 0.98
Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab (2007) 0.98
Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release (2010) 0.98
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
Microsurgical testis-sparing surgery in small testicular masses: seven years retrospective management and results. Urology (2012) 0.96
Thyroid transcription factor-1 facilitates cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the brain. J Biol Chem (2007) 0.95
Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid (2002) 0.95
Bulbar urethroplasty with dorsal onlay buccal mucosal graft and fibrin glue. Eur Urol (2006) 0.95
Open versus laparoscopic partial nephrectomy for clinical T1a renal masses: a matched-pair comparison of 280 patients with TRIFECTA outcomes (RECORd Project). World J Urol (2013) 0.94
Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. Surgery (2009) 0.93
Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun (2003) 0.93
Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. J Clin Endocrinol Metab (2014) 0.93
Overoxidation of peroxiredoxins as an immediate and sensitive marker of oxidative stress in HepG2 cells and its application to the redox effects induced by ischemia/reperfusion in human liver. Free Radic Res (2005) 0.93
Extracellular ATP stimulates the early growth response protein 1 (Egr-1) via a protein kinase C-dependent pathway in the human osteoblastic HOBIT cell line. Biochem J (2003) 0.93
TTF-1, a homeodomain-containing transcription factor, participates in the control of body fluid homeostasis by regulating angiotensinogen gene transcription in the rat subfornical organ. J Biol Chem (2003) 0.93
Relationship between vascular endothelial growth factor and nuclear factor-kappaB in renal cell tumors. Croat Med J (2008) 0.93
Expression of fetal hemoglobin in adult humans exposed to high altitude hypoxia. Blood Cells Mol Dis (2012) 0.93
Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer (2004) 0.93
Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res (2008) 0.92
Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. Int J Geriatr Psychiatry (2010) 0.92
Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol Cell Endocrinol (2004) 0.92
Multiple catecholamine-secreting paragangliomas: diagnosis after hemorrhagic stroke in a young woman. Endocr Pract (2008) 0.92
Retroperitoneal laparoendoscopic single-site surgery: preliminary experience in kidney and ureteral indications. Eur Urol (2010) 0.92
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb (2010) 0.92
Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res (2007) 0.92
Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab (2005) 0.91
Activation of endothelial nitric-oxide synthase by tumor necrosis factor-alpha: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3' kinase, and Akt. Mol Pharmacol (2003) 0.91
Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem (2008) 0.91
Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology (2014) 0.90
Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer (2005) 0.90
Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells. Colloids Surf B Biointerfaces (2013) 0.90
The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production. PLoS One (2010) 0.90
Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol (2002) 0.90
Beneficial effects of the olive oil phenolic components oleuropein and hydroxytyrosol: focus on protection against cardiovascular and metabolic diseases. J Transl Med (2014) 0.90
Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab (2008) 0.90